Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
- Conditions
- LeukemiaLymphomaMultiple MyelomaMyelodysplastic Syndromes
- Interventions
- Radiation: Total body irradiationBiological: Umbilical cord blood unit with C3a fragmentBiological: Unmanipulated UCB Unit
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 31
- Registration Number
- NCT00963872
- Locations
- 🇺🇸
University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Peritoneal Cavity CancerFallopian Tube CancerOvarian Cancer
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00903630
- Locations
- 🇺🇸
University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 19
- Registration Number
- NCT00895414
- Locations
- 🇺🇸
Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
- Conditions
- LeukemiaLymphoma
- Interventions
- Biological: DT2219ARL
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 25
- Registration Number
- NCT00889408
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Scott and White Cancer Institute, Temple, Texas, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Iron Overload in Patients Undergoing Donor Stem Cell Transplant
- Conditions
- Hematopoietic Stem Cell TransplantationCancerAllogeneic Hematopoietic Cell Transplantation
- Interventions
- Procedure: magnetic resonance imagingProcedure: Serum ferritin
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 112
- Registration Number
- NCT00888316
- Locations
- 🇺🇸
University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00882206
- Locations
- 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
- Conditions
- Leukemia
- Interventions
- Biological: aldesleukinProcedure: umbilical cord blood transplantationRadiation: total-body irradiation
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 2
- Registration Number
- NCT00871689
- Locations
- 🇺🇸
University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States
Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
- Conditions
- Lymphoproliferative Disorder
- Interventions
- Biological: rituximab
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT00869323
- Locations
- 🇺🇸
University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States
🇺🇸Washington University School of Medicine - Oncology Division, Saint Louis, Missouri, United States
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
- Conditions
- Breast Cancer
- Interventions
- Procedure: therapeutic conventional surgery
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00855114
- Locations
- 🇺🇸
University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Conditions
- Myelodysplastic SyndromeLeukemia
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT00818649
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States